GlassScriptPhysician profile
Leann M Byrd
NPI 1104808906
$1,867.22
in general payments reported to CMS, 2019-2025
25 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $35.14 · 2021: $258 · 2022: $375 · 2023: $365 · 2024: $308 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $416.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $406.55 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $133.09 | 2019-2024 | |
| Heartflow, INC. | $111.91 | 2025 | |
| Philips North America LLC | $92.39 | 2022 | |
| Xeris Pharmaceuticals, INC. | $92.20 | 2022-2025 | Gvoke Hypopen |
| Abbvie INC. | $78.99 | 2024 | |
| Dexcom, INC. | $73.99 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $67.40 | 2021-2024 | |
| Amgen INC. | $65.22 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $41.49 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.61 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.22 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.85 | 2022-2024 | |
| Lilly USA, LLC | $28.09 | 2022-2023 | Mounjaro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $28.04 | 2023-2025 | Eliquis |
| Abbott Laboratories | $23.14 | 2025 | Eterna |
| Esperion Therapeutics, INC. | $17.74 | 2021 | |
| Acadia Pharmaceuticals INC | $15.41 | 2021 | |
| Medtronic, INC. | $14.20 | 2021 | |
| Eisai INC. | $13.28 | 2021 | |
| Boston Scientific Corporation | $13.22 | 2024 | |
| Mannkind Corporation | $13.02 | 2022 | |
| Daiichi Sankyo INC. | $12.98 | 2022 | |
| Insulet Corporation | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leann Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.